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Abstract Since the publication of the European Association
of Nuclear Medicine (EANM) procedural guidelines for ra-
dionuclide myocardial perfusion imaging (MPI) in 2005,
many small and some larger steps of progress have been
made, improving MPI procedures. In this paper, the major
changes from the updated 2015 procedural guidelines are
highlighted, focusing on the important changes related to
new instrumentation with improved image information and
the possibility to reduce radiation exposure, which is further
discussed in relation to the recent developments of new Inter-
national Commission on Radiological Protection (ICRP)
models. Introduction of the selective coronary vasodilator
regadenoson and the use of coronary CT-contrast agents for
hybrid imaging with SPECT/CT angiography are other
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important areas for nuclear cardiology that were not included
in the previous guidelines. A large number of minor changes
have been described in more detail in the fully revised version
available at the EANM home page: http://eanm.org/
publications/guidelines/2015_07_EANM_FINAL_
myocardial_perfusion_guideline.pdf.
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Preamble
The 2015 update of the European procedural guidelines for
radionuclidemyocardial perfusion imaging (MPI) with single-
photon emission computerized tomography (SPECT) was de-
veloped on the initiative of the Cardiovascular Committee of
the European Association of Nuclear Medicine (EANM) [1].
The guidelines summarize the views of the Cardiovascular
Committee of the EANM and reflect recommendations for
which the EANM cannot be held responsible. The recommen-
dations should be taken into the context of good practice of
nuclear medicine, and they do not substitute for national and
international legal or regulatory provisions. The guidelines
were brought to the attention of all other EANM Committees
and to the National Societies of Nuclear Medicine and have
been approved by the EANM.
The present guidelines are based on the guidelines from
2005 [2]. The 2015 update includes all aspects of SPECT
imaging from gating to hybrid imaging, but does not include
myocardial perfusion evaluated by positron emission tomog-
raphy (PET), which will be updated in a separate guideline.
The 2015 guideline also updates relevant sections of the
2008 guidelines on radionuclide imaging of cardiac function
[3] and the 2011 joint position statement on hybrid cardiac
imaging [4].
The 2015 EANM guidelines on myocardial perfusion im-
aging (MPI) include the following sections:
1. Patient information and preparation
2. Radiopharmaceuticals and CT contrast agents





8. Quality control of instrumentation and image acquisition
9. Reconstruction methods
10. Attenuation and scatter correction
11. Data analysis of regional perfusion imaging
12. Data analysis of left ventricular function
13. Data analysis of hybrid imaging
14. Reports and image display.
All sections have been updated and a lot of details were
revisited. The present paper highlights the major changes
presented in the updated 2015 guidelines and focuses on
the selective coronary vasodilator regadenoson, recent devel-
opments on calculated radiation exposure [i.e., new Interna-
tional Commission on Radiological Protection (ICRP)
models, dedicated cardiac SPECT cameras and hybrid sys-
tems], recent developments in instrumentation (i.e., dedicat-
ed cardiac SPECT and cardiac hybrid imaging systems) and
coronary CT-contrast agents. All 14 sections are described in
more detail in the fully revised version available at the
EANM home page [1].
The EANM guidelines are intended to present information
specifically adapted to European practice, based on evidence
from original scientific studies or on previously published
guidelines [i.e., for the 2015 MPI guidelines as well as for
the extract presented below: on national or European guide-
lines for MPI, on the European Society of Cardiology (ESC),
and on the American College of Cardiology (ACC) / Ameri-
can Heart Association (AHA) / American Society of Nuclear
Cardiology (ASNC) guidelines]. In case of a lack of published
evidence, opinions are based on expert consensus and are
indicated as such. Where more than one solution seems to
be practised, and none has been shown to be superior to the
others, the committee has tried to specifically express this state
of knowledge.
The selective coronary vasodilator regadenoson
Mechanism of action
Vasodilators induce myocardial hyperaemia mediated by
adenosine receptors independent of myocardial oxygen de-
mand. Only A2A receptors induce coronary vasodilation, and
hereby a fourfold to fivefold increase in myocardial blood
flow in healthy coronary vessels. Besides, the A2A receptor
adenosine also stimulates A1, A2B, and A3 adenosine recep-
tors, which provoke the adverse effects [5]. Regadenoson is a
selective stimulator of the A2A receptor with minimal or no
stimulation of the other adenosine receptor subtypes [5].
Dipyridamole increases the tissue levels of adenosine by
preventing the intracellular reuptake and deamination of aden-
osine [5]. Vasodilatation results in a modest increase in heart
rate and most often a modest decrease in both systolic and
diastolic blood pressures.
For regadenoson, as with the other vasodilators, caffeine-
containing beverages (coffee, tea, cola, etc.), foods (chocolate,
etc.), some medicaments (e.g., pain relievers, stimulants and
weight control drugs) and methylxanthine-containing medica-
tions that antagonise vasodilator action must be discontinued
at least 12 h before vasodilator stress and at least five half-lives
before for long-acting methylxanthines. Dipyridamole or
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medications containing dipyridamole should be interrupted
for at least 24 h. Pentoxifylline and clopidogrel need not be
discontinued. Ticagrelor, a direct-acting P2Y12-adenosine di-
phosphate receptor blocker, has been shown to significantly
raise adenosine plasma levels so that more frequent and more
severe adverse effects in adenosine and dipyridamole stress
testing are likely [6, 7]. Interactions with regadenoson have
not yet been studied. So far there are still no recommendations
for dose modification of vasodilators in stress testing for pa-
tients receiving ticagrelor.
Indications
The indications are the same as for exercise MPI, but refer to
patients who are not able to or who are expected to be unable
to achieve ≥ 85 % of maximal age-predicted heart rate during
exercise. Vasodilators (without exercise) should be preferred
to exercise in cases of left bundle branch block or ventricular
paced rhythms (Fig. 1). Considering diagnostic performance
of MPI, there is no significant difference among the stress
agents and modalities [8–10].
Combination with low-level exercise
Low-level exercise can be performed routinely in conjunc-
tion with vasodilator tests. Low-level exercise significantly
reduces vasodilator-induced side effects (flushing, dizzi-
ness, nausea, headache, hypotension) and improves image
quality due to lower bowel activity and higher target-
background ratio. Accordingly, if possible, low-level exer-
cise is recommended in combination with vasodilator
stress testing [11, 12].
Regadenoson dose
Regadenoson is given as a slow bolus over 10 s followed by a
10 s flush of 5–10 ml NaCl 0.9 %, and 10–20 s later the radio-
pharmaceutical is injected (Fig. 2). Regadenoson is adminis-
tered independent of patient weight in a dose of 0.4 mg in 5 ml.
Regadenoson safety profile
Compared to adenosine, regadenoson is associated with a
lower incidence of chest pain, flushing, and throat, neck, or
jaw pain, a higher incidence of headache and gastrointestinal
discomfort and a lower combined symptom score in nearly all
subgroups [13]. The safety of regadenoson was also studied in
two randomized, double-blind, placebo-controlled crossover
trials in patients with mild to moderate asthma and moderate
to severe chronic obstructive pulmonary disease (COPD), re-
spectively. Although dyspnoea was reported in the
regadenoson groups compared to none in the placebo groups,
there was no relation with a decline in forced expiratory vol-
ume in 1 s (FEV1) [14, 15]. Thus, regadenoson can also be
used in patients with mild asthma and COPD. In summary,
despite their selectivity to the A2A receptor, side effects related
to activation of the other adenosine receptors continue to oc-
cur, albeit at a lower frequency and with less severity and
duration compared to the selective adenosine agonists.
A less frequent but important side effect of regadenoson is
a low but significant increase in incidence of seizures. The
exact incidence is unknown and the pathophysiological mech-
anism behind this increased incidence is not yet clear.
Regadenosonmay lower seizure threshold, and aminophylline
should not be used in cases of seizures associated with
regadenoson. These seizures may be of new onset, or may
be recurrences. In addition, some seizures are prolonged and
Fig. 1 Selection of stress test
modality. Except for patients with
left bundle branch block (LBBB)
or ventricular paced rhythm,
consider combining
pharmacological vasodilatory
stress with low-level exercise
according to the ability of the
patient to exercise. In case of
pharmacological stress with
dobutamine but without adequate
heart rate response, consider to
add atropine
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may require urgent anticonvulsive management. It is recom-
mended that during the initial triaging of patients, they should
be asked about a history of seizures [16–18].
According to the available limited data, the absolute risk
of a transient ischaemic attack (TIA) and cerebrovascular
accident (CVA) associated with regadenoson administration
appears to be small and may not be different from other
stress agents [19]. However, based on recent advice from
the European Medicines Agency, a Direct Healthcare Pro-
fessional Communication updated the regadenoson product
information [20]:
& As aminophylline increases the risk of prolongation of a
regadenoson-induced seizure, it should therefore not be
administered solely for the purpose of terminating a sei-
zure induced by regadenoson
& Delay regadenoson administration in patients with elevat-
ed blood pressure until the latter is well controlled
& There is a rare but undesirable risk of a TIA and CVA
associated with regadenoson administration.
Radiation exposure: new ICRP models
The ICRP has adopted new phantoms for absorbed dose cal-
culations, new weighting factors, and new bio-kinetic models
[21–23]. Using these new models, the effective doses per ad-
ministered unit of activity to adults are [24]:
& 99mTc-tetrofosmin (stress and rest): 0.0058 and
0.0063 mSv/MBq, respectively
& 99mTc-sestamibi (stress and rest): 0.0066 and 0.0070 mSv/
MBq, respectively
& 201Tl-chloride (redistribution): 0.102 mSv/MBq.
These values are approximately 20% lower than the values
calculated using the previous methods.
Activity amounts to inject
Camera systems based on new technology (e.g., cadmium-
zinc-telluride (CZT)-cameras) have improved count sensitivi-
ty. This improved sensitivity can be used to either reduce the
amount of activity accordingly, or decrease image acquisition
duration [25–29]. The activities to be administered for paedi-
atric patients should be modified according to the recommen-
dations of the EANM [30].
Hybrid systems
If the MPI is combined with CT for attenuation, calcium scor-
ing (CACS) or coronary CT angiography (CCTA), an addi-
tional dose is given to the patient. For an attenuation correc-
tion CT, an additional 0.5–1.0 mSv is given. Absorbed doses
from CACS and CCTA depend on the system and imaging
protocol used, and for CACS can be estimated to be < 1 mSv.
The absorbed dose for CCTA can be estimated to be between
2–5mSv using commonly available single-source 64-slice CT
scanners with a prospectively ECG-triggered, step-and-shoot
acquisition protocol [31, 32]. The latest generation dual-
source or 256-slice and 320-slice single source CT scanners
enable even absorbed doses < 1 mSv [33, 34].
Instrumentation: dedicated cardiac systems
Since the publication of the first version of this guideline,
some significant advances in technology for cardiac imaging
have been made [35–37]. In new-generation, dedicated cardi-
ac, ultrafast-acquisition scanners, multiple detectors surround-
ing the patient simultaneously image the heart. Variations in
these newly designed, dedicated cardiac scanners comprise
the number and type of scanning or stationary detectors and
the use of NaI, CsI, or CZTsolid-state detectors. They all have
in common the potential for a fivefold to tenfold increase in
count sensitivity at no loss of resolution, resulting in the po-
tential for acquiring a scan in 2 min or less if the patient is
injected with a standard activity. Some of this gain in sensi-
tivity can be traded for a linear reduction in the injected activ-
ity to reduce the patients’ exposure to radiation. With an ul-
trafast camera with a tenfold increase in sensitivity using con-
ventional radiopharmaceutical activity, the dose could be re-
duced by half and a fivefold increase in sensitivity would still
be maintained [36].
Dedicated systems have emerged based on traditional scin-
tillation detector technology, equipped with smaller crystals
and thus having more compact design, as well as truly inno-
vative cameras with a completely novel detector technology.
Pixelated, solid-state detectors made of CdZnTe (an alloy of
Fig. 2 Timeline of regadenoson
plus low-level exercise testing.
BPM beats per minute
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cadmium telluride and zinc telluride, CZT) offer better energy
resolution and a virtually linear count rate response. As CZT
replaces both the scintillation crystal and the attached
photomultiplier tubes, the detectors are very compact. This
has thus far been exploited in two different, commercially
available cameras. The D-SPECT® (Spectrum Dynamics) uti-
lises nine small rectangular detectors placed along a 90° arc.
Each detector rotates around its own axis. All detectors togeth-
er register photons from an area comparable to a traditional
180° acquisition. The other CZT system (the Discovery
NM530c by GE Healthcare) uses a stationary, multiple-
pinhole design with 19 holes, each with its own CZT detector.
The collimators are arranged such that the area of the chest
including the heart can be imaged. Clinical evaluations of both
systems have demonstrated performance similar to that of tra-
ditional systems, but with shorter imaging times or lower ad-
ministered activities [36]. In a recent study, the D-SPECT®
system was compared to a conventional SPECT camera,
showing improved image quality, comparable incidence of
extracardiac activity, and achieving a reduction in absorbed
dose to 1 mSv for a single injection [38].
Another variation from traditional design is the upright
patient position offered in a number of dedicated systems.
While more comfortable for the patient, the effect of posture
on organ position must be considered when interpreting the
images [39, 40]. Some cameras systems (e.g., Digirad
Cardius) go one step further and employ a rotating patient
chair instead of a rotating gantry. Additionally, CsI(Tl) detec-
tors allow for an optional X-ray-based attenuation correction
method. Another variation of the upright design (the
CardiArc system) is based on three stationary arc-shaped
crystals combined with a moving aperture, providing a simi-
lar function as a collimator. A problem with many different,
dedicated cardiac systems is the scarcity of publications about
their clinical validity [36].
An upgraded technology (IQ-SPECT, Siemens Healthcare)
uses a conventional multi-purpose SPECT system with a ra-
dially oriented, symmetric, cardio-focal collimator that is
characterised by a radially increasing focal spot distance.
The proprietary reconstruction algorithmmatches the collima-
tors’ spatially varying sensitivity profile. Reductions in acqui-
sition time with no loss in image quality are claimed, but the
clinical evidence is limited.
Instrumentation: SPECT/CT hybrid systems
The SPECT detectors in most SPECT/CT systems do not dif-
fer in any significant way from those of stand-alone SPECT
systems. The SPECT sub-systems are typically large field of
view (FOV), variable-angle, dual detector system. For hybrid
imaging systems, the CT configuration can be a low-
resolution CT (non-diagnostic CT) or a multi-detector-row
CTwith slices ranging from 2 up to 64. Any of these systems
can be used for attenuation correction of MPI. For CACS, at
least 4-slice CT is required, but ≥ 6-slice recommended. For
CCTA, at least a 16-slice scanner is required, but a ≥ 64-slice
multidetector-row CT is recommended, with an imaging ca-
pability for slice width of 0.4–0.6 mm and temporal resolution
of 500 ms or less; ≤ 350 ms is preferred [41, 42].
In general, it has to be considered that CT imaging is much
faster than SPECT, where the heart position is averaged over
the complete acquisition time (5–20 min), so that mis-
registration artefacts can occur. As a consequence, free-
breathing and end-expiratory breath-hold protocols during
CT scanning are preferred over inspiration breath-hold proto-
cols when the CT scan is performed for attenuation correction
only [43]. General guidelines for CT-based transmission im-
aging for SPECT are listed in Table 1 [44].
For attenuation correction of perfusion SPECTstudies, sep-
arate CTscans should be performed for the rest and stressMPI
studies, even if recent studies demonstrate that the CT trans-
mission scans are interchangeable in specific clinical settings
[45]. Other recent studies have demonstrated that the CT scan
can be used to approximate the extent of coronary calcifica-
tion [46]. This approach, however, is less accurate as com-
pared to dedicated calcium scans due to missing correction
of the coronary motion and a much lower photon density.
Otherwise, the coronary artery calcium score CT scan can be
used for attenuation correction, but with the limitation that this
scan may not register adequately with SPECT due to different
acquisition time points [47, 48]. These are topics of ongoing
research and software developments.
For detailed acquisition protocols of the coronary artery
calcium scan and CCTA we refer to the joint position state-
ment by the EANM, the ESCR and the European Council of
Nuclear Cardiology [4].
Coronary CT contrast agents
The use of contrast media for cardiac imaging is increasing
as hybrid cardiac SPECT/CT and PET/CT, as well as coro-
nary CT angiography and cardiac MRI, become more widely
used [4].
For coronary CT angiography (CCTA), an intravenously
injected contrast agent is needed. In general, these contrast
agents are iodine-based and due to the relatively high attenu-
ation coefficient of iodine, therefore result in high contrast
between organs with and those without contrast. Coronary
CT in combination with ECG-gating and a contrast agent per-
mits visualization of the coronary artery lumen and detection
of coronary artery stenoses [49, 50]. At the moment, there are
four classes of contrast media available for clinical use: high
osmolar ionic monomers, low osmolar non-ionic monomers,
low osmolar ionic dimers and iso-osmolar non-ionic dimers.
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The contrast media are provided at various iodine concentra-
tions and have different biochemical properties (viscosity, os-
molarity, hydrophilic behaviour, ionic content and pH).
In general, the injection protocol should follow vendor rec-
ommendations dependent on the specific contrast agent and
CT used. For coronary imaging in general, a contrast agent
with a high concentration of iodine is used (300–400 mg/ml)
to ensure adequate opacification of the small coronary arteries
[51]. In total, approximately 60–90 ml of contrast agent is
injected at an injection speed of 4–6 ml/s. Often the bolus is
split between a first bolus of pure contrast and then a bolus
with a mix of contrast and saline, to reduce streak artefacts
from contrast enhancement of the vena cava and right side of
the heart. Otherwise, the contrast bolus is followed by a saline
flush of 40–70ml. With the newest generation of CTscanners,
a smaller contrast bolus with lower iodine concentration is
likely sufficient to obtain good contrast enhancement of the
coronary arteries [52].
Two contrast timing techniques are available to start the
CCTA acquisition, based on the arrival of contrast in the aorta:
the bolus tracking and the bolus timing technique. Bolus
tracking involves a series of axial low-dose images at 2 s
intervals to track the arrival of the bolus of contrast material
in the aorta. The CCTA is initiated when the contrast enhance-
ment of the aorta reaches a certain predefined level, e.g., 100
Hounsfield units (HU). The bolus timing technique involves
an extra low-dose scan acquisition of a single slice prior to the
CCTA acquisition. Here, a small contrast bolus and saline
flush are injected to determine the contrast arrival interval.
The time between the start of the contrast injection and the
arrival of contrast bolus in the aorta is used as the scan delay
for the actual CCTA [4, 49].
Contraindications
Contraindications for iodine contrast can be divided into ab-
solute and relative contraindications [53, 54]. Absolute
contraindications include myasthenia gravis, mastocytosis,
and post-thyroid carcinoma when follow-up with 131I imaging
or 131I therapy is planned within 6 months of the CCTA.
Relative contraindications are known contrast allergy, planned
thyroid scan, and multiple myeloma.
The most frequent problem is related to renal failure: The
clinical benefit of using estimated glomerular filtration rate
(eGFR) or calculated creatinine clearance in assessing pre-
procedural, contrast induced nephrotoxicity (CIN) risk in pa-
tients with stable renal function is uncertain, because much of
the knowledge comes from studies that used only serum cre-
atinine measurements. The threshold values at which different
clinical actions should be taken (e.g., active IV hydration,
avoidance of contrast medium administration) are neither
proven nor generally agreed upon for either serum creatinine
measurement or calculated creatinine clearance. In addition,
the accuracy of these formulae has only been validated in the
patient population for whom they were developed. The fol-
lowing is a suggested list of risk factors that may warrant pre-
administration serum creatinine screening in patients who are
scheduled to receive intravascular iodinated contrast medium.
This list should not be considered definitive [55]:
& Age>60
& History of renal disease, including dialysis, kidney trans-
plant, single kidney, renal cancer, renal surgery
& History of hypertension requiring medical therapy
& Diabetes.
Metformin does not confer an increased risk of CIN. How-
ever, metformin can very rarely lead to lactic acidosis in patients
with renal failure. In case of reduced renal function (i.e., esti-
mated glomerular filtration rate<45ml/min/1.73m2, or < 60ml/
min/1.73 m2 in the presence of diabetes or ≥ 2 risk factors for
contrast nephropathy), alternative imaging strategies should be
considered. However, when no alternatives are available, ade-
quate hydration is the major preventive action against CIN.
Table 1 General guidelines for CT-based transmission imaging for SPECT [44]
CT parameter General principle Effect on patient absorbed dose
Slice collimation Collimation should approximate slice thickness
of SPECT (e.g., 4–5 mm)
Thinner collimation often less dose efficient
Gantry rotation speed Slower rotation helps blurring cardiac motion
(e.g., 1 s/revolution or slower)
Increased radiation with slower gantry rotation
Table feed per gantry rotation (pitch) Pitch should be relatively high (e.g., 1:1) Inversely related to pitch
ECG gating ECG gating is not recommended Decreased without ECG gating
Tube potential 80–140 kVp is used, depending on manu
facturer specification
Increases with higher kVp
Tube current Because scan is acquired only for attenuation correction,
low tube current is preferred (10–20 mA)
Increases with higher mA
Breathing instructions End-expiration breath-hold or shallow free breathing is preferred No effect
Reconstructed slice thickness Thickness should approximate slice thickness
of SPECT (e.g., 4–7 mm)
No effect
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If intravenous contrast agent is going to be administered,
metformin should be discontinued at the time of the proce-
dure and withheld for 48 h after the procedure. If the risk of
nephrotoxicity is high, metformin can be reinstituted only
after renal function has been re-evaluated and found to be
normal. If the risk of nephrotoxicity is low, metformin can be
re-instituted without the need for renal function assessment.
An alternative glucose-controlling drug should be considered
during this time [56].
Adverse events
Strategies to reduce the risk in non-acute, contrast medium
induced, adverse reactions include the prophylactic use of
oral anti-histamines and corticosteroid tablets. A classifica-
tion system, stratifying adverse events due to iodinated
contrast media by severity and type, is presented below
[55, 57, 58]:
& Minor Signs and symptoms are self-limited without evi-
dence of progression. Mild reactions include: pruritus,
nausea and mild vomiting, diaphoresis
& Moderate: Signs and symptoms are more pronounced and
commonly require medical management. Some of these
reactions have the potential to become severe if not treat-
ed. Moderate reactions include: facial oedema, faintness,
severe vomiting, urticaria, bronchospasm
& Severe: Signs and symptoms are often life-threatening and
can result in permanent morbidity or death if not managed
appropriately. Severe reactions include: laryngeal oedema,
pulmonary oedema, respiratory arrest, hypotensive shock,
convulsions, cardiac arrest
& Delayed: Skin rash, thyrotoxicosis, kidney dysfunction.
The frequency of allergic-like and physiologic adverse
events related to the intravascular administration of iodinated
contrast media is low and has decreased considerably with
changes in usage from ionic, high-osmolality contrast agents
(HOCA) to non-ionic, low-osmolality contrast agents
(LOCA). Historically, acute adverse events occurred in 5–
15 % of all patients who received HOCA. Many patients
receiving intravascular HOCA experienced physiologic dis-
turbances (e.g., generalized warmth, nausea, or emesis), and
this was often documented as a contrast reaction. HOCA are
now rarely or never used for intravascular purposes, because
of their greater adverse event profile compared to LOCA.
The reported overall acute adverse reaction rate (allergic-like
+ physiologic) for non-ionic LOCA (i.e., iohexol,
iopromide, or iodixanol) ranges from 0.2 %, 0.6 % to
0.7 % [59–61]. Serious acute reactions to iv. LOCA are rare,
with a historical rate of approximately four in 10,000
(0.04 %) [62].
Reconstruction methods
Myocardial perfusion images are the result of a complex re-
construction process. Although sophisticated reconstruction
methods are available, including correction for motion, atten-
uation and scatter correction, these software tools cannot pro-
duce Bmiracles^. It is therefore important to achieve optimal
quality of the raw data by selecting the proper matrix size,
angular sampling, zoom factor, patient-to-camera distance,
energy window settings, and assuring that the camera is prop-
erly tuned and maintained through regular quality control
procedures. In addition, the acquired projection data should
be checked for motion and the presence of high extra-cardiac
uptake. This should be done before the patient leaves the
department and before reconstruction is commenced.
Camera vendors and various third party companies provide
reconstruction software that implement iterative reconstruc-
tion based on Ordered Subset Expectation Maximisation or
maximum likelihood expectation maximization (OS-EM/
ML-EM). The advantage of these algorithms over traditional
filtered-back projection is that information about the camera,
patient and radiopharmaceutical can be exploited to recon-
struct better images. CT images can be incorporated for esti-
mation of attenuation and scatter; the collimator-detector-
response can be modelled and used for resolution recovery;
noise can be compensated by modelling the underlying char-
acteristics of the decay process.
These reconstruction methods can achieve enhanced image
quality that may be traded against shorter acquisition times or
reduced administered activity. Fundamental to all these algo-
rithms is the correct choice of user-selectable parameters (typ-
ically number of iterations and subsets, regularisation, and
filter parameters). Inadequate parameters most likely lead to
insufficient image quality and artefacts. As implementations
vary considerably across vendors, it is not possible to transfer
settings between camera systems without prior validation.
Currently, all major vendors offer the possibility to include
resolution recovery (also called count recovery) in the OS-EM/
ML-EM algorithm. The increased reconstructed resolution and
lower noise allow for slightly lower count statistics (hence low-
er injected activity) or shorter scan times [35]. However, such
techniques require careful testing against phantom studies per-
formed with validated hardware and software.
Data analysis of hybrid imaging
Hybrid imaging is defined as the combination and fusion of two
data sets by which both modalities significantly contribute to
image information [63]. Typically, hybrid imaging is synergis-
tic, i.e. more powerful than the sum of its parts, as it provides
information beyond that achievable with either data set alone,
leading to improved sensitivity and specificity (Fig. 3).
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The term hybrid imaging is not valid for the combination of
nuclear cardiac imagingwith X-ray-based ACwhere the (low-
dose) CT images do not provide independent information, but
only contributes to image quality improvement of the other
modality (SPECT) [4].
Hardware and software requirements
Dedicated workstations capable of two-dimensional and
three-dimensional displays of CCTA and SPECT data are a
basic requirement for hybrid data analysis. Aside from projec-
tion of standard views of SPECT data, the combination of
hardware and software has to offer capabilities for volume
rendering of stress and rest SPECT data sets (uncorrected
and attenuation corrected), common reconstruction and
reformatting techniques for CCTA data [including transaxial
stacks, multiplanar (curved) reformations, maximum intensity
projections and volume-rendering] [64], and automatic or
manual image co-registration and fusion. If non-contrast en-
hanced CT data is acquired for AC of SPECT, the software
should offer computation of coronary artery calcium scores.
Integration of myocardial perfusion SPECTwith CCTA
The incremental value of hybrid cardiac imaging arises from
spatial co-localization of a myocardial perfusion defect with a
subtending coronary artery. Traditionally, this process is per-
formed by mental integration of a standard myocardial seg-
mentation model that allocates each segment to one of the
three main coronary arteries [65].
Notably, however, there is a substantial inter-individual
anatomical variability of coronary arteries. Therefore, the
so-called standard distribution of myocardial perfusion
territories does not correspond with the patients’ individual
anatomy in more than half of the patients [66]. Most frequent-
ly, the left circumflex artery segments are erroneously
assigned to the right coronary artery territory, and standard
left anterior descending artery segments are erroneously
assigned to the left circumflex territory [67]. True hybrid
cardiac imaging and data analysis using volume rendered,
co-registered, and fused SPECT and CCTA data sets should
be preferred over sole side-by-side analysis because of accu-
rate segmental assignment to coronary artery territories and
documented incremental value [68–70].
Fused images of myocardial perfusion SPECT and CCTA
can be obtained using data sets acquired on a hybrid scanner
(SPECT/CT) or via co-registration of images obtained from
separate stand-alone scanners. Software-based automated reg-
istration is accurate and fast [70]. However, automated co-
registration of data from cardiac imaging is more challenging
than that from other body areas. Errors may arise from cardiac
motion, breathing motion, and cardiac contraction [71]. Addi-
tionally, different anatomic features are depicted by the two
modalities rendering automatic object recognition and image
registration difficult, particularly if large perfusion defects are
present in SPECT images. Accurate registration, however, is
of utmost importance to accurately allocate subtending coro-
nary arteries to areas with radiotracer uptake. Therefore, re-
view of the registration is mandatory and manual correction
must be performed if needed.
Data analysis
The combined diagnostic information from myocardial perfu-
sion SPECT imaging and CCTA is complementary: the neg-
ative predictive value of CCTA to exclude CAD is close to
Fig. 3 Coronary artery territories in a 17-segment model Myocardial
perfusion SPECT, coronary computed tomography angiography
(CCTA), and fused hybrid SPECT/CCTA of a 43-year-old male patient
with presenting symptoms of typical angina. Myocardial perfusion
SPECT documents a reversible perfusion defect in short axis and
horizontal long axis slices (a) at rest (bottom rows) and stress (top
rows). The corresponding polar plots (b) at rest (left plot) and stress
(right plot) clearly depict the extent of the ischaemic area in the
anterolateral wall. CCTA (c) shows an intermediate stenosis (i.e., 50–
70 % luminal narrowing) due to non-calcified plaques in the middle/
distal left anterior descending artery at the level of the second diagonal
branch bifurcation. Fused hybrid SPECT/CCTA (d) reveals that the
anterolateral ischaemia corresponds with the vascular territory of the
second diagonal branch, while the stenosis in the left anterior
descending artery (LAD) does not cause any ischaemia
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perfect (Fig. 3) [49, 72, 73]. However, specificity and positive
predictive value of CCTA for identification of haemodynam-
ically significant luminal narrowing have been documented to
be less robust. CCTA is associated with a general overestima-
tion of the severity of coronary artery stenosis and difficulties
to differentiate between slight differences in stenosis severity.
SPECToffers complementary diagnostic information as to the
haemodynamic significance of coronary artery lesions detect-
ed by CCTA. Also, uninterpretable segments on CCTA due to
strong calcifications or artefacts can be well studied with
SPECT. By contrast, CCTA adds to the diagnostic value of
SPECT through documentation of multivessel disease (with
possible balanced ischaemia not detectable by semi-
quantitative SPECT analysis) or diagnosis of subclinical
atherosclerosis.
Interpretation of CCTA studies is beyond the scope of this
document and is covered in detail in the respective guidelines
of the Society of Cardiovascular Computed Tomography [64].
In brief, CCTA should be first reviewed in transaxial images,
complemented by multiplanar reformations to better visualize
suspected lesions. Diagnostic conclusions are not based on
three-dimensional, volume-rendered CCTA representations.
By contrast, in hybrid imaging, a panoramic three-
dimensional view is offered by integrating volume-rendered
CT data with the perfusion information from SPECT. This
comprehensive information improves both the identification
of the culprit vessel and the diagnostic confidence for catego-
rizing intermediate lesions and equivocal perfusion defects,
thus optimizing management decisions.
Incidental cardiac and extracardiac CT findings are not
uncommon [74]. Although most such findings are negligible,
some may occasionally be of clinical relevance. Thus, it is
recommended that images are additionally screened by a phy-
sician fully trained in CT readings, including non-contrast
enhanced CT scans for attenuation correction and scouts.
On a practical level, this concept requires careful coordina-
tion of the readout between nuclear physicians and radiolo-
gists, and the final discussion with the cardiologist. The ben-
efit of such an interdisciplinary approach is that those fully
trained in the specific modalities would interpret the images
jointly, thus providing a high-quality result covering all as-
pects of hybrid SPECT/CCTA image acquisition.
The integration of coronary anatomy by CCTA and
(quantitative) documentation of the ischaemic burden through
SPECT allows effective identification of: 1) patients with
CAD benefitting from optimal medical therapy versus those
who should undergo coronary revascularization, 2) the culprit
stenosis in patients with multiple coronary artery lesions,
thereby guiding clinicians on the appropriate method of revas-
cularization, 3) patients with subclinical coronary atheroscle-
rosis where more aggressive prevention may be indicated, and
4) patients with normal coronary arteries who can safely be
deferred from any further cardiac testing.
In summary, the complimentary anatomic and functional
information provided by hybrid SPECT/CCTA imaging has
been demonstrated to confer added diagnostic value in CAD
detection [67, 69, 70, 75, 76] and to effectively stratify risk and
predict outcomes [77, 78], guide patient management [79], and
to contribute to optimal downstream resource utilization [80].
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